Sona Nanotech Appoints Michael A. Fleming to Board of Directors
Sona Nanotech (SONA.CN) on Thursday said it appointed Michael Fleming to its board of directors.Fleming served as executive vice president for commercial operations and subsequently as chief strategy officer of Coherus BioSciences, said the company.Earlier in his career, Fleming held senior leadership roles at Elan, Genentech, and GlaxoSmithKline, where he "directed global commercial strategy across multi-billion-dollar franchises and led numerous product launches across oncology, infectious disease, metabolic and specialty therapeutics", added the company."We are delighted to welcome Michael as a director to the company," said board chair Mark Lievonen. "Sona will benefit from Michael's significant biotech business experience built over a 35-year career guiding emerging life science companies through critical value inflection points including capital formation, clinical development, and strategic transactions. His direct experience with immune-oncology assets and the relationships he brings will be valuable."Shares of the company were last seen unchanged at $0.27 on the Canadian Securities Exchange.
